Audited Financial Results for the Half year and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts more than Nifty Microcap 250 and 4.9 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Longlife Hospital and Research Ltd reported audited FY25 results showing a near-total collapse in its core business. Revenue from operations fell sharply from ₹1,351.45 lakhs in FY24 to just ₹57.73 lakhs in FY25, a drop of about 96%, with revenue for the second half of FY25 being effectively zero. Despite this, the company swung to a net profit of ₹19.87 lakhs from a loss of ₹218.81 lakhs in FY24, but this turnaround was driven almost entirely by a jump in other income to ₹501.61 lakhs (vs ₹6.33 lakhs), largely from selling fixed assets worth ₹2,417 lakhs and redeeming mutual funds. The company also became completely debt-free, repaying all long-term (₹341 lakhs) and short-term borrowings (₹933 lakhs), and its cash pile ballooned from ₹38.54 lakhs to ₹2,149.18 lakhs. The statutory auditor M/s R B Gohil & Co. issued an unmodified opinion on the results.
This is a worrying picture for shareholders — the hospital business appears to have been wound down or sold off, and the profit figure is not from operations but from asset disposals. With no operating revenue and the company essentially sitting on cash after selling its productive assets, the long-term business case looks unclear, which is likely to weigh negatively on the stock.